Study the levels of Leptin, and Adiponectin with Paraoxonase in Obese Individuals (male & female)
Article Sidebar
Main Article Content
Abstract
Obesity is a well-known risk factor of metabolic complications and cardiovascular disease. Associations between anthropometric measurements and fat distribution and risk factors for cardiovascular disease have been demonstrated in several populations.
To study the association of various measures of body mass index (BMI), waist circumference (WC), percentage of body fat (%BF), with leptin, Adiponectin, and paraoxonase. To study the association between leptin , adiponectin with Paraoxonase.
This study conducted from of February 2013 until March 2014, all individuals were randomly recruited from Kirkuk and Tikrit Governorate .Hormonal assay of leptin, adiponectin, Paraoxonase, and glucose. Blood samples collected from 220 individuals, and these samples were divided into three groups according to BMI. Group 1 (Normal Weight group n=80), Group 2 (Over Weight group, n=58), Group 3 (Obese group, n=62) .
The statistical analysis (students t-test) exhibited significant (P≥ 0.0001)elevation for leptin , paraoxonase, and glucose, while significant decrease in adiponectin in over weight and obese groups compared with normal weight groups.
The correlation coefficient (r) between Leptin and other parameters were calculated with regression plot showed a negative correlation with adiponectin, and paraoxonase in over weight and obese group. There was a positive correlation between adiponectin with paraoxonase, but a negative correlation with leptin, in over weight and obese group.
Conclusion: Adiponectin as hormone play an important role in the prevention of hyperlipidemia, and consequently atherosclerosis and its complications while Leptin act as atherosclerotic factors. The results indicated that adiponectin positively associated with paraoxonase while Leptin negatively correlated with paraoxonase.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
1. WHO. World Health Organization Fact Sheet for World Wide Prevalence of Obesity. Available online: hhtp://www.who. int/media center/factsheets/fs311/en/index html(accessed on 11 February 2013).
2. Alexandra Manuela Stoianov. Elongation Factor 1A-1 and Hepatocyte Response to Fatty Acid Excess. [MSc Thesis]. Ontario, Canada: University of Western Ontario;2013
3. Karagiannides I. Torres D., Tseng Y., Bowe C., Carvalho E., Espinoza D., Pothoulakis C., and Okotou E. Substance P as a Novel Anti-obesity Target. Gastroenterology. 2008; 134:747–755.
4. Chaudhri O, Wynne K, Bloom S . Can Gut Hormones Control Appetite and Prevent Obesity? Diabetes Care. 2008; 284.
5. El-Nuweihy, N. T. El-Melegy, N. F. Ameen and E. M. Radwan. Role of Adiponectin in Patients with Non-Insulin Dependent Diabetes Mellitus. Bull. Pharm. Sci., Assiut University. 2010;. 33, 2: 107-120.
6. Adil B. Relationship of Leptin Hormones with Body Mass Index and Waist Circumference in Saudi Female Population of the Makkah Community; The Open Obesity Journal, 2010; 2, 95-100
7. Mackness, M., Mackness, B.,. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? Free Radicals. Biol Med, 2004; 37, 1317–1323.
8. Suman S Dambal, Suchetha Kumari N. Evaluation of lipid peroxidation and total antioxidant status in human obesity; International Journal of Institutional Pharmacy and Life Sciences2012;2(3): 2249-6807.
9. WHO . Steps Manual. Part 3 Training and Practical Guides. Geneva: WHO 2008.
10. Fried, M. ; Hainer, V. ; Basdevant, A. etal. "Inter-disciplinary European guidelines on surgery of severe obesity". International Journal of Obese. Lond , 2007; 31 (4) : 569–77.
11. Tietz, N.W. (1995) Clinical Guide to laboratory tests. 3rd ed. W.B. Saunders, Philadephia. 578-580.
12. Mackness, M.I., D. Harty, D. Bhatnagar, P.H. Winocour, S. Arrol, M. Ishola, and P.N. Durrington. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis. 1991;86:193–199.
13. Ioannis T, Maria K, Evangelia P, Sophia T, Konstantinos N. The Role of Leptin in Cancer
Pathogenesis. Journal of Cancer Therapy. 2013; 4: 640-650.
14. Considine RV, Sinha MK, Heiman ML, et al. Serum immune-reactive leptin concentrations in normal weight and obese humans. N Engl J Med 1996; 334: 292-5.
15. Kristina S, Dalibor D, Radivoje R, Vedrana V, Robert S,Robert Steiner, Ivica Bošnjak. Overweight - early stage of “adipokines related cardiovascular diseases”: leptin and adiponectin relation to anthropometric parameters. Med Glas Ljek komore Zenicko-doboj kantona. 2012; 9(2):198-203.
16. Wang Z, Nakayama T. Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm. 2010; 535918.
17. Ursula Mand Axel M. ''Endocrine Regulation of Energy Metabolism: Review of Pathobiochemical and Clinical Chemical Aspects of Leptin, Ghrelin, Adiponectin, and Resistin.'' Clinical Chemistry. 2009; 9;1511–1525.
18. Mattsson C, Olsson T. Estrogens and glucocorticoid hormones in adipose tissue metabolism. Current Medicine Chemistry. 2007; 14: 2918-24.
19. De Konig L, Merchant AT, Pogue J, Anand SS. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. European Heart Journal. 2007; 28:850-56.
20. Takashi K and Toshimasa Y. '' Adiponectin and Adiponectin Receptors.'' Japan; and Core Research for Evolutional Science and Technology of Japan Science and Technology Agency.2005;3:32-42.
21. Mamaghani F, Zarghami N, Maleki MJ, Pourhassan - Moghaddam M, Hossein panah F. Variation of Adiponectin Levels in Normal and Obese subjects: Possible Correlation with Lipid Profiles. International Journal of Endocrinology Metabolism 2009;3:170-178.
22. Hassani, F. The Relevance of Adiponectin and Resistin Levels, with Oxidative stress in Insulin Resistant in T2 diabetic. [MSc Thesis]. Kufa: College of Medicine in Iraq;2011.
23. Toshimitsu Y. ,Shoichiro N. , Ataru T. , Mitsuo F. ,Tomoatsu N. , Akira K.et al. "Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus" . Metabolism ;2003;52, 1274-78 .
24. Marcovina SM, Albers JJ, kennedy H, mei JV , Henderson LO, Hannon WH, "IV comparability of Apo lipoprotein B values by use of international reference materials". Clinical Chemistry ; 1994, 40: 586-92
25. Philip AK , Gina BD, Tong Lu, Negah R ,Gouri R ,"Adiponectin expression from human adipose tissue" . diabetes ; 2003,52; 1179-85.
26. Mohamed-Ali V,pinkney JH ,Coppack SW, " Adipose tissue as an endocrine and paracrine organ" . Int. J. Obes ; 1998, 22: 1145-1158.
27. Xu, A., et al.. "Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes". J. Biol. Chem;2005, 280:18073-18080.
28. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H et al. "Androgens decrease plasma adiponectin, an insulin sensitizing adipocyte derived protein" . Diabetes; 2002 ,51 ,2734–2741.
29. Combs TP, Berg AH, Rajala MW, Klebanov S, Iyengar P, Jimenez-Chillaron JC, Patti ME, Klein SL, Weinstein RS & Scherer PE. "Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte specific secretory protein adiponectin" . Diabetes;2003, 52 ,268–276.
30. Baratta R, Amato S, Degano C, Farina MG, Patane G, Vigneri R, et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both crosssectional and intervention studies. Journal Clinical Endocrinol Metab , 2004; 89: 2665-671.
31. Giamila F, and Theodore M. '' Adipose Tissue and Atherosclerosis.''Arterioscler Thromb Vasc Biol.2009 ;27:996-1003.
32. Oliye O, Huriye B, serdal U, Erkan C, Hafize U, Cihat S, Can G, and Engin E. The relationship of leptin, adiponectin levels and paraoxonase activity with metabolic and cardiovascular risk factors in females treated with psychiatric drugs. Clinics 2008;63(5)651-60.
33. Ferretti G, Baccheti T, Moroni C et al .Paraoxonase activity in high density lipoproteins: a comparison between healthy and obese females. Journal Clinical Endocrinology Metabolism, 2005; 90: 1728–1733.
34. Audikovszky M, Pados G, Seres I et al. Orlistat increases serum paraoxonase activity in obese patients. Nutr Metab Cardiovasc Dis ,2007;17:268–273.
35. Rector RS, Warner SO, Liu Y, et al. Exercise and diet induced weight loss improves measures of oxidative stress and insulin sensitivity in adults with characteristics of the metabolic syndrome. American Journal Physiological Endocrinololgy Metabolism. 2007; 293: 500‑506.
36. Kazuhiko K, Nakane K, Sano Y et al . Changes on the physiological lactonase activity of serum paraoxonase 1 by a diet intervention for weight loss in healthy overweight and obese women. Journal Clinical Biochem Nutr.2009; 45:329–334.
37. Tabur S, Torun AN, Sabuncu T. Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation. European Journal Endocrinology ,2010; 162:535–541.
38. Mehmet A, Mehmet H, Tevfik S, Hakim C, Sahbettin S. Serum paraoxonase enzyme activity and
oxidative stress in obese subjects. Polskie Archiwum Medycyny Wewnetrzne J 2011; 121 (6).
39. Sorenson RC, Bisgaier CL, Aviram M, et al. Human serum Paraoxonase/Arylesterase’s retained hydrophobic N‑terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A‑I stabilizes activity. Arterioscler Thromb Vasc Biol. 1999; 19: 2214-2225.
40. Beltowski J, Wo Jcicka G, Jamroz A. Leptin decreases plasma Paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis 2003;170:21-9.
41. Sunil K. Kota, Lalit K. Meher, Siva K. Kota, Sruti Jammula, S.V.S. Krishna, Kirtikumar D. Modi. Implication of serum Paraoxonase activity in obesity, diabetes mellitus, and dyslipidemia. Indian Journal of Endocrinology and Metabolism:2013-17-3.
42. Bajnok L, Seres I, Varga Z, Jeges S, Peti A, Karanye Z, et al. Relation of serum resistin level to traits of metabolic syndrome and serum Paraoxonase
-1 activity in a population with broad range of body mass index. Clinical Endocrinology Diabetes 2008; 116:592-9.
43. Maria F, Francine C, Tális S, Alencar K, Fernanda B, Marta M, Ivana B. Impact of obesity and Ala16Val MnSOD polymorphism interaction on lipid, inflammatory and oxidative blood biomarkers. Open Journal of Genetics, 2012; 2: 202-209.
44. She Z-G, Chen H-Z, Yan Y, Li H, Liu D-P. The Human Paraoxonase Gene Cluster as a Target in the Treatment of Atherosclerosis. Antioxid Redox Signal. 2012 ,15;16(6):597-632.
45. Grdic M, Rumora L, Barisic K. The paraoxonase 1,2 and 3 in humans. Biochemia Medica. 2011; 21(2):122-30.
46. Lorena C, Ştefan C, Eleonora D, Dorel P.,Vasile C. Vlad, Maria S, Cadariu A. Distribution of Paraoxonase 1 polymorphisms and activities in obese patients; Revista Română de Medicină de Laborator, 2013; 21, 4/4.